SANGAMO THERAPEUTICS INC
SGMO
SGMO was delisted on the 4th of May, 2026.
184 hedge funds and large institutions have $744M invested in SANGAMO THERAPEUTICS INC in 2019 Q3 according to their latest regulatory filings, with 24 funds opening new positions, 59 increasing their positions, 41 reducing their positions, and 25 closing their positions.
44% more repeat investments, than reductions
Existing positions increased: 59 | Existing positions reduced: 41
23% more call options, than puts
Call options by funds: $14.9M | Put options by funds: $12.1M
1.73% more ownership
Funds ownership: 69.25% → 70.98% (+1.7%)
1% less funds holding
Funds holding: 185 → 184 (-1)
4% less first-time investments, than exits
New positions opened: 24 | Existing positions closed: 25
14% less capital invested
Capital invested by funds: $860M → $744M (-$116M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MWNA
Marshall Wace North America
New York
|
+$11.6M |
| 2 |
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
|
+$6.07M |
| 3 |
Jennison Associates
New York
|
+$5.78M |
| 4 |
Morgan Stanley
New York
|
+$4.21M |
| 5 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
+$3.36M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$6.28M |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$6.22M |
| 3 |
State Street
Boston,
Massachusetts
|
-$3.69M |
| 4 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$3.03M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.65M |
SGMO Hedge Fund Activity: Q3 2019 in Review
184 of the 4,561 institutional investors tracked by Wall St. Rank reported a position in SANGAMO THERAPEUTICS INC (SGMO) for Q3 2019, worth a combined $744M — down 14% from $860M a quarter earlier.
Sellers outnumbered buyers: 25 funds closed out of SGMO and 24 opened new positions — a net loss of 1 holder — while 41 trimmed existing stakes and 59 added.
The largest buyer was Marshall Wace North America, opening a new position worth an estimated $11.6M. The largest seller was Renaissance Technologies, cutting an estimated $6.28M.
- 184 institutional investors held SANGAMO THERAPEUTICS INC (SGMO) as of Q3 2019, down from 185 in Q2 2019.
- Funds reported $744M of SANGAMO THERAPEUTICS INC stock for Q3 2019, down 14% quarter-over-quarter.
- 24 funds opened new SANGAMO THERAPEUTICS INC positions in Q3 2019 and 25 closed out, a net change of -1 holder.
- The largest SANGAMO THERAPEUTICS INC buyer in Q3 2019 was Marshall Wace North America, an estimated $11.6M added.
- The largest SANGAMO THERAPEUTICS INC seller in Q3 2019 was Renaissance Technologies, an estimated $6.28M sold.
Based on aggregated 13F filings for Q3 2019.